These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14604746)

  • 1. [Type 2 diabetes mellitus pathogenesis: new therapeutic managements?].
    Blicklé JF
    Rev Med Interne; 2003 Nov; 24(11):709-10. PubMed ID: 14604746
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of rapid insulin secretion: revisited.
    Grodsky GM
    Diabetes Technol Ther; 1999; 1(3):259-60. PubMed ID: 11475271
    [No Abstract]   [Full Text] [Related]  

  • 3. [Rapaglinide: Novonorm, an alternative in type 2 diabetes].
    Bouhanick B; Barbosa SS
    Presse Med; 2000 May 27-Jun 3; 29(19):1059-61. PubMed ID: 10874917
    [No Abstract]   [Full Text] [Related]  

  • 4. Insulin secretagogues.
    Kock M
    J Assoc Physicians India; 1997; Suppl 1():48. PubMed ID: 11235637
    [No Abstract]   [Full Text] [Related]  

  • 5. [Mechanisms of action of repaglinide at a cellular level].
    Thomsen MK
    Diabetes Metab; 1999 Dec; 25 Suppl 7():11-3. PubMed ID: 10746004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.
    Owens DR
    Eur J Clin Invest; 1999 Jun; 29 Suppl 2():30-7. PubMed ID: 10383608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Insulin secretion and repaglinide].
    Owens D
    Diabetes Metab; 1999 Dec; 25 Suppl 7():17-9. PubMed ID: 10746006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Repaglinide in combination therapy in type 2 diabetes].
    Moses R
    Diabetes Metab; 1999 Dec; 25 Suppl 7():26-7. PubMed ID: 10746009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prandial glucose regulator for type 2 diabetic patients. Beta cells produce insulin according to need].
    MMW Fortschr Med; 1999 Sep; 141(36):61. PubMed ID: 10904606
    [No Abstract]   [Full Text] [Related]  

  • 10. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide dose response? A clinician's viewpoint.
    Schade DS
    Diabetes Technol Ther; 1999; 1(3):257-8. PubMed ID: 11475270
    [No Abstract]   [Full Text] [Related]  

  • 12. Improving management of type 2 diabetes mellitus: 4. Meglitinides.
    Quillen DM; Kuritzky L; Samraj GP
    Hosp Pract (1995); 1999 Dec; 34(13):38-40. PubMed ID: 10611897
    [No Abstract]   [Full Text] [Related]  

  • 13. Honing type 2 diabetes treatment.
    Blackburn G
    Health News; 2001 Jan; 7(1):1-2. PubMed ID: 11198405
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulinotropic meglitinide analogues.
    Dornhorst A
    Lancet; 2001 Nov; 358(9294):1709-16. PubMed ID: 11728565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR; Cozma LS; Luzio SD
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE
    Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy in type 2 diabetes: the role of repaglinide.
    Moses R
    J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
    de Luis DA; Aller R; Cuellar L; Terroba C; Ovalle H; Izaola O; Romero E
    Diabetes Care; 2001 Oct; 24(10):1844-5. PubMed ID: 11574456
    [No Abstract]   [Full Text] [Related]  

  • 20. Repaglinide for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.